A randomized study of decitabine versus conventional care for maintenance therapy in
patients with acute myeloid leukemia in complete remission | Leukemia Skip to main …

Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60
years old have a 5-year survival rate of less than 8%. In an attempt to improve this …

Purpose To determine an optimal biologic dose (OBD) of decitabine as a single agent and
then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in …

Background Vitamin C suppresses leukaemogenesis by modulating Tet methylcytosine
dioxygenase (TET) activity. However, its beneficial effect in the treatment of patients with …

Background: Relapse remains the most common cause of treatment failure after intensive
induction and consolidation (CONS) therapy in older adults with AML. We therefore …

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated
with poor outcomes, especially in high‐risk AML/MDS. Allogeneic hematopoietic stem cell …

We read with great interest the report by Daskalakis et al1 on the regulation of the
expression of cyclin-dependent kinase inhibitor p15, an inhibitor of G1/S progression, in …

This post hoc analysis of the DACO-016 phase III study evaluates the impact of decitabine
on transfusion dependence and survival in 485 elderly patients with newly diagnosed acute …

Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients
with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax …

Introduction: Overexpression of the antiapoptotic protein BCL-2 has been implicated in the
maintenance and survival of acute myelogenous leukemia (AML) cells and associated with …